WO2015060650A2 - 간세포 성장인자의 둘 이상의 이형체를 이용한 근위축성 측삭 경화증 예방 또는 치료용 조성물 - Google Patents
간세포 성장인자의 둘 이상의 이형체를 이용한 근위축성 측삭 경화증 예방 또는 치료용 조성물 Download PDFInfo
- Publication number
- WO2015060650A2 WO2015060650A2 PCT/KR2014/009971 KR2014009971W WO2015060650A2 WO 2015060650 A2 WO2015060650 A2 WO 2015060650A2 KR 2014009971 W KR2014009971 W KR 2014009971W WO 2015060650 A2 WO2015060650 A2 WO 2015060650A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hgf
- sequence
- pck
- cells
- isoforms
- Prior art date
Links
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 title claims abstract description 78
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 title claims abstract description 78
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 title claims abstract description 42
- 239000000203 mixture Substances 0.000 title claims abstract description 32
- 108010029485 Protein Isoforms Proteins 0.000 title claims abstract description 24
- 102000001708 Protein Isoforms Human genes 0.000 title claims abstract description 24
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 42
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 42
- 239000002157 polynucleotide Substances 0.000 claims abstract description 42
- 239000004480 active ingredient Substances 0.000 claims abstract description 8
- 239000002773 nucleotide Substances 0.000 claims description 54
- 239000013598 vector Substances 0.000 claims description 43
- 108090000623 proteins and genes Proteins 0.000 claims description 42
- 125000003729 nucleotide group Chemical group 0.000 claims description 38
- 238000000034 method Methods 0.000 claims description 29
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 239000013612 plasmid Substances 0.000 claims description 11
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 claims description 10
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 7
- 108020004414 DNA Proteins 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 5
- 102100021866 Hepatocyte growth factor Human genes 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 108091061960 Naked DNA Proteins 0.000 claims 1
- 208000034189 Sclerosis Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 109
- 230000000694 effects Effects 0.000 description 21
- 210000003050 axon Anatomy 0.000 description 20
- 239000006228 supernatant Substances 0.000 description 20
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 19
- 230000014509 gene expression Effects 0.000 description 19
- 230000010261 cell growth Effects 0.000 description 16
- 150000001413 amino acids Chemical group 0.000 description 14
- 230000006907 apoptotic process Effects 0.000 description 13
- 241000701161 unidentified adenovirus Species 0.000 description 13
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 12
- 239000012091 fetal bovine serum Substances 0.000 description 12
- 210000002161 motor neuron Anatomy 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 11
- 239000002609 medium Substances 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 102220020162 rs397508045 Human genes 0.000 description 10
- 230000030833 cell death Effects 0.000 description 9
- 239000002299 complementary DNA Substances 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 241000700605 Viruses Species 0.000 description 8
- 102000057308 human HGF Human genes 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 238000001890 transfection Methods 0.000 description 8
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 7
- 101150022655 HGF gene Proteins 0.000 description 7
- 238000001415 gene therapy Methods 0.000 description 7
- 230000002068 genetic effect Effects 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 230000036542 oxidative stress Effects 0.000 description 7
- 241001430294 unidentified retrovirus Species 0.000 description 7
- GQMMRLBWXCGBEV-YVMONPNESA-N (nz)-n-[(3-nitrophenyl)methylidene]hydroxylamine Chemical compound O\N=C/C1=CC=CC([N+]([O-])=O)=C1 GQMMRLBWXCGBEV-YVMONPNESA-N 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 210000003205 muscle Anatomy 0.000 description 6
- 238000010899 nucleation Methods 0.000 description 6
- 238000003753 real-time PCR Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000001476 gene delivery Methods 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 239000002502 liposome Substances 0.000 description 5
- 230000035800 maturation Effects 0.000 description 5
- 208000005264 motor neuron disease Diseases 0.000 description 5
- 210000002569 neuron Anatomy 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 239000013603 viral vector Substances 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 238000002869 basic local alignment search tool Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000012790 confirmation Methods 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000035784 germination Effects 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 108700024394 Exon Proteins 0.000 description 3
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 3
- 101150024147 bax gene Proteins 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000007917 intracranial administration Methods 0.000 description 3
- 238000007914 intraventricular administration Methods 0.000 description 3
- 201000010901 lateral sclerosis Diseases 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000001177 retroviral effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 230000004543 DNA replication Effects 0.000 description 2
- 241000702421 Dependoparvovirus Species 0.000 description 2
- 108700039887 Essential Genes Proteins 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101100230980 Homo sapiens HGF gene Proteins 0.000 description 2
- 241001135569 Human adenovirus 5 Species 0.000 description 2
- 238000010818 SYBR green PCR Master Mix Methods 0.000 description 2
- 229910000831 Steel Inorganic materials 0.000 description 2
- 230000006909 anti-apoptosis Effects 0.000 description 2
- 108700041737 bcl-2 Genes Proteins 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000007012 clinical effect Effects 0.000 description 2
- 238000009223 counseling Methods 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 210000002241 neurite Anatomy 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000010959 steel Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- 108020003589 5' Untranslated Regions Proteins 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 239000013607 AAV vector Substances 0.000 description 1
- 101150108397 Abcd2 gene Proteins 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 1
- 101100232904 Homo sapiens IL2 gene Proteins 0.000 description 1
- 101100232919 Homo sapiens IL4 gene Proteins 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 101100321817 Human parvovirus B19 (strain HV) 7.5K gene Proteins 0.000 description 1
- 101150102264 IE gene Proteins 0.000 description 1
- 101150103227 IFN gene Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 244000062730 Melissa officinalis Species 0.000 description 1
- 235000010654 Melissa officinalis Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 241001028048 Nicola Species 0.000 description 1
- 241001505332 Polyomavirus sp. Species 0.000 description 1
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000012578 cell culture reagent Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 108700004025 env Genes Proteins 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108700004026 gag Genes Proteins 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000007674 genetic toxicity Effects 0.000 description 1
- 231100000025 genetic toxicology Toxicity 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000006654 negative regulation of apoptotic process Effects 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 230000007514 neuronal growth Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 108700004029 pol Genes Proteins 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical group [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000009163 protein therapy Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012502 risk assessment Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 210000001032 spinal nerve Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
Definitions
- the present invention relates to a composition for preventing or treating atrophic lateral sclerosis comprising two or more heterologs of hepatocyte growth factor or polynucleotides encoding the heterologs as an active ingredient.
- ALS Amyotrophic Lateral Sclerosis
- ALS a progressive neurodegenerative disease characterized by the following characteristics: ALS, neurological disorders, neurological disorders, and many others: ALS, neurological disorders, and many others: ALS, neurological disorders, and many others: ALS, neurological disorders, and many others: ALS, neurological disorders, and many others: ALS, neurological disorders, and many others: ALS, neurological disorders, and many others: ALS, neurological disorders, and many others: ALS, neurological disorders, and many others: ALS, neurological disorders, neurological disorders, and others.
- Molecular genetic testing which can be used in clinical trials involving several genes related to ALS, plays an important role in genetic type diagnosis and genetic counseling.
- ALS can be inherited by autosomal dominant, autosomal recessive, or X-linked methods. Genetic counseling and risk assessment depend on the exact diagnosis of a specific genetic diagnosis.
- Ri luzol e is known as a drug that delays the progression of ALS disease. have. Rirusol is known to slow down the progression of ALS by inhibiting excess glutamic acid, which is thought to be one of the causes of motor neuron destruction.
- the clinical effects of rilusol do not improve the symptoms of ALS and the results are not clear in increasing the duration of tracheostomy-free survival in patients with ALS.
- the true clinical effects of rilusol which is beneficial to ALS patients, have been reported to be very limited and ambiguous (Stewart et al, 2001). Nevertheless, since there is no effective prophylactic or therapeutic agent for ALS in addition to the ambiguous clinical usefulness of the rurusol, there is a need for the development of drugs that exhibit a prophylactic or therapeutic effect on ALS.
- PCT / KR03 / 000548 discloses a composition for treating or preventing ischemic disease or liver disease, including the pCK-HGFX7 recombinant vector used in the present invention. All contents of PCT / KR99 / 000855 and PCT / KR03 / 000548 are incorporated herein by reference. Throughout this specification, many papers and patent documents are referenced and their citations are indicated. The disclosures of cited papers and patent documents are incorporated herein by reference in their entirety, and the level of the technical field to which the present invention belongs and the contents of the present invention are more clearly explained.
- the present inventors made diligent research efforts to develop a drug capable of preventing or treating amyotrophic lateral sclerosis. As a result, the present invention has been found by identifying that two or more hepatocyte growth factor (HGF) isoforms or a composition comprising a polynucleotide encoding the variants as an active ingredient can be used to treat ALS. It was completed.
- HGF hepatocyte growth factor
- the object of the present invention is Amyot rophi c Lateral Scleros is) to provide a pharmaceutical composition for the prevention or treatment.
- Another object of the present invention is to provide a method for preventing or treating Amyotrophi c Lateral Scleros is.
- the invention is HGF (Hepatocyte Growth)
- ALS can be treated using a composition comprising two or more Hepatocyte Growth Factor (HGF) isoforms or polynucleotides encoding the variants as an active ingredient.
- HGF Hepatocyte Growth Factor
- the therapeutic strategies of the present invention can be broadly classified into two groups: protein therapy and gene therapy.
- protein therapeutic strategy of the present invention two or more types of heterologous proteins of HGF are used.
- gene therapy strategy of the present invention one or more nucleotide sequences encoding two or more types of heterologs of HGF are used.
- Two or more types of HGF isoform-encoding nucleotide sequences may be provided as one polynucleotide or as separate polynucleotides.
- two or more types of HGF isoform-encoding nucleotide sequences of HGF are provided as one polynucleotide.
- HGF isoform 1 refers to all alleles.
- HGF isoforms have the meaning encompassing both the normal form or wild type of HGF, and various variants of HGF (eg, splicing variants and deletion variants).
- two or more isoforms of the HGF of the invention comprise full length HGF (ful l length HGF; f lHGF) and a variant HGF (del eted var i ant HGF; dHGF).
- HGF full length HGF
- f lHGF full length HGF
- dHGF variant HGF
- f lHGF refers to the amino acid 1-728 sequence of an animal, preferably a mammal, more preferably a human HGF.
- dHGF refers to a deleted variant of the HGF protein produced by selective spooling of the HGF gene in an animal, preferably a mammal, more preferably the first chunk of the alpha chain from the full length HGF sequence.
- human HGF consisting of 723 amino acids missing five amino acids (F, L, P, S and S) in the ringle domain.
- the full length HGF of the invention comprises the amino acid sequence of SEQ ID NO: 1
- the deleted variant HGF of the invention comprises the amino acid sequence of SEQ ID NO: 2.
- the variants of the HGF of the invention are encoded by separate nucleotide sequences or by a single polynucleotide.
- the pharmaceutical composition of the present invention comprises two or more polynucleotides when different types of HGFs are encoded by separate polynucleotides, and different types of variants of HGF are encoded by a single polynucleotide Where included, one or more polynucleotides comprising the single polynucleotide.
- the polynucleotides of the invention may be operably linked to one or more regulatory sequences (eg, promoters or enhancers) that regulate the expression of HGF isoforms.
- expression cassettes can be constructed in two ways.
- an expression cassette is constructed by linking an expression control sequence to a CDS (cod ing sequence) for each of the variants.
- a CDS cod ing sequence
- the second method using an IRESG nt erna lri bosoma entry site or a 2k peptide in the same manner as "expression control sequence-first variant CDS-IRES-second variant CDS-transcription sequence”.
- Construct an Expression Cassette IRES allows the translation of genes to begin at the IRES sequence so that two or more genes of interest are extracted from the same construct.
- the polynucleotides encoding both of the two or more types of variants are operably linked to a single expression control sequence.
- the variants of HGF may be encoded by a hybrid HGF gene which simultaneously expresses two or more different types of variants, such as f lHGF and dHGF.
- the hybrid HGF gene comprises cDNA corresponding to exons 1 to 18 of human HGF, and intron 4 or a fragment thereof of human HGF gene inserted between axons 4 and 5 of the cDNA.
- the hybrid HGF gene comprises a nucleotide sequence selected from the group consisting of SEQ ID NO: 3 to 10 sequences.
- the hybrid HGF gene comprising intron 4 is 7113 bp in length and comprises the nucleotide sequence of SEQ ID NO: 3.
- the hybrid HGF gene may optionally comprise a fragment of intron 4 between axons 4 and 5 of the HGF cDNA. have.
- the sequence additionally inserted between exons 4 and 5 is intron 4 of the human HGF gene, nucleotides 392 to 2247th of the sequence 3rd sequence, 392th to 727th Nucleotides 2229 th to 5471 th and nucleotides, 5117 th to 5471 th nucleotides, 3167 th to 5471 th nucleotides, 4167 thru 5471 th Nucleotides or combinations thereof.
- the sequence additionally inserted between axons 4 and 5 of the therapeutic nucleotide sequence used in the present invention comprises (i) the nucleotides 392 to 2247 of the 3rd sequence in SEQ ID NO: 3 and the 2229 th to 5471 th Nucleotides of (ii) the 392 th to 2247 th nucleotides of sequence 3rd sequence and the nucleotides 5117 to 5471 th of (3) the 392 th to 2247 nucleotides and 3167 th of sequence 3rd sequence Nucleotides 5471 through 5471, (iv) nucleotides 392 through 2247 of the sequence 3rd sequence and nucleotides 4167 through 5471, and ( v ) 392 through 727th sequence of the 3rd sequence Nucleotides and nucleotides 2229 to 5471, (vi) SEQ ID NO: 3 sequence Nucleotides 392 through 727 and nucleotides 5117 through 5471, (vi) S
- the therapeutic nucleotide sequence of the present invention according to the sequence additionally inserted between the axons 4 and 5 is as follows: (i) (axons 1 to exon 4)-(SEQ ID NO: 392 to 2247) Nucleotides from -2229 to 5471 nucleotides)-(exon 5 to axon 18); (ii) (exons 1 to axon 4)-(nucleotides 392 to 2247 of SEQ ID NO: 3-nucleotides from 5117 to 5471)-(axons 5 to exon 18); (iii) (axons 1 to exon 4)-(nucleotides 392 to 2247 of SEQ ID NO: 3-nucleotides 3167 to 5471)-(exon 5 to exon 18); (iv) (axons 1 to axon 4)-(nucleotides 392 to 2247 of SEQ ID NO: 3-nucleotides 4167
- HGF-X the hybrid HGF gene including the fragment of Intron 4
- HGF-X has HGF-X2, HGF- having a nucleotide sequence of SEQ ID NO: 4 to 10 X3, HGF-X4, HGF-X5 HGF-X6, HGF-X7 and HGF—X8.
- HGF-X7 is preferably used.
- HGF isoforms "HGF-X”, “HGF-X7”, and the like have been reported in the prior art PCT / KR03 / 000548, and the disclosures of the patent documents are described herein in their entirety. Is inserted by reference.
- the amino acid or nucleotide sequence of the HGF isoforms usable in the present invention are also construed to include amino acid or nucleotide sequences that exhibit substantial identity with the sequence of wild type human HGF isoforms.
- the substantial identity is minimal when the amino acid or nucleotide sequence of the wild-type human HGF isoform is aligned with the maximal correspondence with any other sequence, and when the aligned sequence is analyzed using algorithms commonly used in the art.
- Biol. 215: 403-10 (1990)) are accessible from the National Center for Biological Information (NBCI) and the like, and sequence analysis such as blastp, blasm, blastx, tblastn and tblastx on the Internet. Can be used in conjunction with the program.
- BLSAT is available at http: //www.ncbi. Accessible at nlm.nih.gov/BLAST/. Sequence homology comparison methods using this program can be found at http://www.ncbi.nlm.nih.gov/BLAST/blast_help.html.
- prevention refers to the administration of the compositions of the present invention. By all means any action that inhibits or delays progression of amyotrophic lateral sclerosis.
- treatment refers to (a) inhibition of the development of amyotrophic lateral sclerosis; (b) alleviation of amyotrophic lateral sclerosis; Or (c) removal of amyotrophic lateral sclerosis.
- composition of the present invention enables the prevention or treatment of amyotrophic lateral sclerosis through neural pole germination and growth in neurons, and the growth and death of motor neurons.
- compositions of the present invention can be applied in vivo through various delivery methods commonly known in the art of gene therapy.
- the polynucleotide of the present invention is naked DNACnaked DNA) or is included in a gene carrier.
- gene carriers include plasmids, vectors and viral vectors.
- Plasmids can be used as carriers to carry the polynucleotides of the invention.
- the polynucleotides included in the vector are preferably present in a suitable expression cassette.
- the polynucleotide in the expression cassette is preferably operably linked to a promoter.
- operably linked refers to a functional binding between a nucleic acid expression control sequence (eg, an array of promoters, signal sequences or transcriptional regulator binding sites) and other nucleic acid sequences, whereby the regulation The sequence will control the transcription and / or translation of said other nucleic acid sequence.
- a promoter bound to a polynucleotide sequence is a promoter derived from a mammalian virus, capable of controlling transcription of the nucleotide sequence by operating in an animal cell, preferably a mammalian cell, and more preferably a human cell.
- promoters derived from genomes of mammalian cells including, for example, the cyt omega lo virus (CMV) promoter, the late adenovirus promoter, the vaccinia virus 7.5K promoter, the SV40 promoter, the tk promoter of HSV, the RSV promoter, EF1 alpha Promoter, metallothionine promoter, beta-actin promoter, promoter of human IL-2 gene, promoter of human IFN gene, promoter of human IL-4 gene, promoter of human lymphospecific gene and promoter of human GM-CSF gene Including but not limited to.
- CMV cyt omega lo virus
- the late adenovirus promoter the late adenovirus promoter
- the vaccinia virus 7.5K promoter the SV40 promoter
- the tk promoter of HSV the RSV promoter
- EF1 alpha Promoter metallothionine promoter
- beta-actin promoter promoter of human IL-2 gene
- the promoter used in the present invention is a promoter or EF1 alpha promoter derived from an IE (immediately early) gene of human CMV (hCMV), most preferably the promoter / enhancer and exon 1 whole of the hCMV IE gene. 5'-UTR (untranslated region) comprising the sequence from immediately before the ATG start codon of exon 2.
- the expression cassette used in the present invention may comprise a polyaninated sequence, for example, a plastic field hormone terminator (Gimmi, ER, et al., Nucleic Acids Res. 17: 6983—6998 (1989)), derived from SV40 Poly adenylation sequence (Schek, N, et al., Mol. Cell Biol. 12: 5386-5393 (1992)), HIV-1 polyAC lasens, BIF, et al. , Nucleic Acids Res. 26: 1870-1876 (1998)), ⁇ —globin polyA (Gil, A., et al, Cell 49: 399-406 (1987)), HSV TK polyA (Cole, CN and TP Stacy, Mol. Cell. Biol 5: 2104—2113 (1985)) or polyomavirus polyA (Batt, D. B and GG Carmichael, Mol. Cell. Biol. 15: 4783-4790 (1995)).
- a pCK, pCP, pVAXl or pCY vector may be used as a carrier of the polynucleotide, and more preferably, a pCK vector may be used.
- the pCK vector is disclosed in detail in WO 2000/040737, the disclosure of which is incorporated herein by reference in its entirety.
- Retroviruses are widely used as gene transfer vectors because they insert their genes into the host genome, carry large amounts of foreign genetic material, and have a broad spectrum of infectable cells.
- the polynucleotide sequence of the present invention is inserted into the retrovirus genome instead of the sequence of the retrovirus to produce a nonreplicating virus.
- constructing packaging cell lines containing gag, pol, and env genes but without LTR (long terminal repeat) and ⁇ sequences Mann et al., Cell, 33: 153-159 (1983)).
- the ⁇ sequence enables the production of RNA transcripts of the recombinant plasmid, which transcript is packaged as a virus, and the virus is Discharged to the medium (Nicolas and Rubinstein "Retroviral vectors," In: Vectors: A survey of molecular cloning vectors and their uses, Rodriguez and Denhardt (eds.), Stoneham: Butterworth, 494-513 (1988)).
- the medium containing the recombinant retrovirus is collected, concentrated and used as a gene delivery system.
- Adenoviruses are widely used as gene transfer vectors due to their medium genome size, ease of manipulation, high titers, wide range of target cells and excellent infectivity. Both ends of the genome contain 100-200 bp of Inverted Terminal Repeat (ITR), which is a cis-element essential for DNA replication and packaging.
- ITR Inverted Terminal Repeat
- the genome's E1 regions (E1A and E1B) represent the transcriptional and host cell genes. Encode proteins that regulate transcription.
- the E2 regions (E2A and E2B) encode proteins that are involved in viral DNA replication.
- the polynucleotide sequence of the present invention is preferably inserted into the deleted E1 region (E1A region and / or E1B region) or E3 region.
- the nucleotide sequence may be inserted into the deleted E4 region.
- deletion as used herein in connection with a viral genome sequence has the meaning including not only a complete deletion of the sequence, but also a partial deletion.
- adenovirus can pack up to about 105% of the wild-type genome, about 2 kb can be additionally packaged (Ghosh— Choudhury et al., EMBO J., 6: 1733-1739 (1987)).
- the above-described foreign sequence inserted into the adenovirus may additionally bind to the genome of the adenovirus.
- Adenoviruses have 42 different serotypes and subgroups of A-F. Of these, adenovirus type 5 belonging to subgroup C is the most preferred starting material for obtaining the adenovirus vector of the present invention. Biochemical and genetic information for adenovirus type 5 is well known. Foreign genes carried by adenoviruses replicate in the same way as episomes, and have very low genetic toxicity to host cells. Therefore, gene therapy using adenovirus gene delivery system is considered to be safe.
- Adeno-associated virus is suitable as the gene delivery system of the present invention because it can infect non-dividing cells and has the ability to infect various kinds of cells. Details of the manufacture and use of MV vectors are disclosed in detail in US Pat. Nos. 5,139,941 and 4,797,368. Studies on AAV as a gene delivery system are described in LaFace et al, Viology, 162: 483486 (1988), Zhou et al. , Exp. Hematol. (NY), 21: 928-933 (1993), Walsh et al, J. Clin. Invest. 94: 1440-1448 (1994) and Flotte et al. Gene Therapy, 2: 29-37 (1995). Recently, MV vectors have been conducting clinical I as a treatment for cystic fibrosis.
- MV viruses are plasmids containing the gene sequence of interest, with two MV terminal repeats located next to them (McLaughlin et al., J. Virol., 62: 1963-1973 (1988); and Samulski et al. , J. Virol., 63: 3822-3828 (1989)) and the expression #rasmid (McCarty et al., J. Virol., 65: 2936-2945 (1991), including the wild type V. coding sequence without terminal repeats. Prepared by co-transfection).
- viral vectors can also be used to carry the polynucleotide sequences of the invention in vivo. Basinian virus (Puhlmann M. et al., Human Gene Therapy 10: 649—657 (1999); Ridgeway, "Mammal i an expression vectors," In: Vectors: A survey of molecular cloning vectors and their uses.Rodrigue and Denhardt Stoneham: Butterworth, 467-492 (1988); Baichwal and Sugden, "Vectors for gene transfer derived from animal DNA viruses: Transient and stable expression of transferred ⁇ genes," In: Kucher 1 apat i R, ed.
- Liposomes are automatically formed by phospholipids dispersed in the aqueous phase. Examples of successfully delivering foreign DNA molecules into liposomes into cells include Nicolau and Sene, Biochim. Biophys. Acta, 721: 185-190 (1982) and Nicolau et al. , Methods Enzymol., 149: 157-176 (1987). Liposomes containing the polynucleotide sequence of the present invention interact with cells through mechanisms such as endocytosis, adsorption to the cell surface, or fusion with plasma cell membranes to transport the polynucleotide sequences into cells.
- the polynucleotide sequence of the present invention when mounted on naked recombinant DNA molecules or plasmids (vectors), the microinjection method (Capecchi, MR, Cell, 22: 479 (1980); and Harland and Weintraub, J. Cell Biol. 101: 1094-1099 (1985)), calcium phosphate precipitation (Graham, FL et al., Virology, 52: 456 (1973); and Chen and Okayama, Mol. Cell. Biol. 7: 2745 -2752 (1987)), electroporation (Neumann, E. et al. ⁇ EMB0 J., 1: 841 (1982); and Tur-Kaspa et al., Mol.
- the polynucleotide sequence of the present invention When the polynucleotide sequence of the present invention is constructed based on a viral vector, the polynucleotide sequence may be transported into cells according to various viral infection methods known in the art. Infection of host cells with viral vectors is described in the above cited references.
- the gene carrier of the invention is a vector.
- the vector of the present invention is a plasmid, most preferably a pCK vector can be used.
- a recombinant vector comprising a single polynucleotide expressing two or more isoforms of HGF using a pCK vector is PCK-HGFX7, as detailed above in PCT / KR99 / 000855 and PCT / KR03 / 000548. It is described.
- composition of the present invention may comprise a pharmaceutically acceptable carrier.
- Pharmaceutically acceptable carriers included in the compositions of the present invention are those commonly used in the formulation, lactose, dextrose, sucrose, sorbbi Manny, Starch, Acacia Rubber, Calcium Phosphate, Alginate, Gelatin, Calcium Silicate, Microcrystalline Cellulose, Polyvinylpyrrolidone, Cellulose, Water, Syrup, Methyl Cellulose, Methylhydroxybenzoate, Propylhydride Oxybenzoate, talc, magnesium stearate, mineral oil, and the like.
- the pharmaceutical composition of the present invention may further include a lubricant, a humectant, a sweetener, a flavoring agent, an emulsifier, a suspending agent, a preservative, and the like.
- a lubricant e.g., talc, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, a kaolin, sorbibuprofate, a sorbi cal Sciences (19th ed., 1995).
- the pharmaceutical composition of the present invention is preferably parenteral administration, such as intravenous administration, intraperitoneal administration, subcutaneous administration, intradermal administration, spinal cord administration, intrathecal administration, intraventricular administration, intracranial administration, intracranial administration, intramuscular Administration may be by administration or by topical administration. Most preferably, intramuscular, intramedullary, intrathecal, intraventricular, intraventricular and intracranial administration can be administered.
- compositions of the invention can be formulated and administered by injection. Suitable dosages of the pharmaceutical compositions of the present invention vary depending on factors such as formulation method, mode of administration, age of patient, weight, sex, degree of disease symptom, time of administration, route of administration, rate of excretion and response sensitivity. In general, the skilled practitioner can readily determine and prescribe a dosage effective for the desired treatment.
- the variants of the HGF of the invention are administered at a dosage of 1 to 2500 mg each, and the polynucleotides encoding the variants are administered at a dosage of 1 to 2500 mg each. Dosages may be the same or different each time when administration of the variants of the HGF or the polynucleotides encoding it is repeated more than once.
- compositions of the present invention are prepared in unit dosage form by being formulated using pharmaceutically acceptable carriers and / or excipients according to methods which can be easily carried out by those skilled in the art. Or may be prepared by incorporation into a multi-dose container.
- the formulation may be in the form of a solution, suspension or emulsion of oil or aqueous medium, or may be in the form of axes, powders, granules, tablets or capsules, dispersants Or stabilizers may additionally be included.
- the present invention provides a muscle comprising administering to a mammal a composition comprising, as an active ingredient, two or more variants of Hepatocyte Growth Factor (HGF) or a polynucleotide encoding the variants.
- HGF Hepatocyte Growth Factor
- a method for preventing or treating Amyotrophic Lateral Sclerosis is provided.
- two or more isoforms of the HGF of the invention include full length HGF (flHGF) and the missing variant HGFCdeleted variant HGF; dHGF).
- the full length HGF of the invention comprises the amino acid sequence of SEQ ID NO: 1
- the deleted variant HGF of the invention comprises the amino acid sequence of SEQ ID NO: 2.
- the method for preventing or treating Amyotrophic lateral sclerosis is a method comprising the step of administering a pharmaceutical composition for preventing or treating Amyotrophic lateral sclerosis, which is an aspect of the present invention. It is omitted to avoid excessive complexity.
- the present invention provides a pharmaceutical composition for preventing or treating Amyotrophic Lateral Sclerosis.
- the present invention provides a method for preventing or treating Amyotrophic Lateral Sclerosis.
- composition or method of the present invention can prevent or treat atrophic lateral sclerosis through suppression of neural pole germination, growth and motor neuron growth and death in embryonic neurons.
- 1 is a neuropolar germination of ENC cells according to an embodiment of the present invention Indicates the effect of pCK-HGFX7.
- Figure 2 shows the effect of pCK-HGFX7 on the growth of ENC cells according to an embodiment of the present invention.
- Figure 3 shows the effect of pCK-HGFX7 on cell growth in NSC-34 cells according to an embodiment of the present invention.
- Figure 4 shows the effect of pCK-HGFX7 on cell death in NSC-34 cells according to an embodiment of the present invention.
- Figure 5 shows the effect of pCK-HGFX7 on the survival of NSC-34 cells in oxidative stress culture conditions according to an embodiment of the present invention.
- Figure 7 shows the effect of pCK-HGFX7 on cell growth in cells delivered with hSODl of the G93A mutant form according to an embodiment of the present invention.
- Figure 8 shows the effect of pCK-HGFX7 on the grip of the mouse in ALS mice according to an embodiment of the present invention.
- NSC 34 cells used in this experiment (Cel hit i on Biosystem, Vancouver,
- CA mouse derived motor neurons.
- NSC-34 cells are a cell line in which motor neurons and neuroblastoma cells derived from spinal nerves of an embryonic mouse are mixed and widely used for research on motor neurons. The cells were cultured at 37 ° C., 5% C0 2 , Dulbecco's Modified Eagle Medium (DMEM, Sigma) containing 10% fetal bovine serum (Gibco BRL, USA) and antibiotics (Gibco BRL, USA). Incubated in-house. Cell culture media, reagents and serum were purchased from Gibco and Sigma aldr i ch.
- DMEM Dulbecco's Modified Eagle Medium
- DNA transfection was used to produce supernatants expressing HGF proteins.
- Transfection uses the FuGene HD Transfection System (Promega, USA). Was used and performed according to the manufacturer's protocol. After seeding 293T cells with 1 ⁇ 10 6 cells, the following day pCK, pCK-HGF728 (pCK-cHGF from PCT / KR03 / 000548), pCK-HGF723 (pCK-dHGF from rcT / KR03 / 000548) and pCK-HGFX7 DNA 3 yg were each transfected. After incubation for 48 hours, each supernatant was harvested and filtered using a 0.22 ⁇ filter.
- HGF protein contained in each supernatant was measured using human HGF immunoassay. Each supernatant was again diluted to 1 yg / mL and used for the experiment.
- Recombinant human HGF protein used in human HGF immunoassay was purchased from R & D (R & D syst em, Inc., USA).
- NSC-34 cells were treated with pCK-HGFX7 and then evaluated for cell proliferation.
- Cells were cultured in culture medium containing 10% fetal bovine serum and then suspended using Dulbecco's Modified Eagle Medium containing fetal bovine serum for use in experiments.
- the cells were suspended in 6-well plates by suspending 3 ⁇ 10 4 cells and cells in 2 mL of a medium containing 1% serum.
- each supernatant obtained from 293T cells transfected with pCK-HGF728, pCK-HGF723, and pCK-HGFX7 was added to each well in a 6 well plate at a concentration of 50 ng / mL.
- the supernatant obtained by transfecting 293T cells with pCK vector was used as a control. After 48 hours of incubation, the medium of the 6-well plate was replaced.
- each supernatant obtained from 293T cells transfected with pCK-HGF728, pC -HGF723, pCK_HGFX7 was prepared with a concentration of HGF protein of 50 ng / After adding to n was incubated for 48 hours.
- the supernatant obtained by transfecting 293T cells with pCK vector was used as a control. Cultured cells were collected to count the cells. pCK vector was used as a control.
- the cells were cultured for 5 days, and compared to the experimental group treated with the pCK vector in the experimental group treated with the supernatant obtained from 293T cells transfected with pCK, pCK-HGF728, pCK-HGF723, and pCK-HGFX7.
- the experimental group treated with pCK-HGF728 or pCK-HGF723 induced about 20% cell proliferation
- an increase of about 48% was observed.
- NSC-34 cells were seeded in 6 well plates suspended in 3 ⁇ 10 4 with Dulbecco's Modified Eagle Medium containing 1% fetal bovine serum. After stabilizing cells for 2 hours after cell seeding, each supernatant obtained from 293T cells transfected with pCK-HGF728, pCK-HGF723, and pCK-HGFX7 was added at a concentration of 50 ng / mL of HGF protein. The supernatant obtained by transfecting 293T cells with pCK vector was used as a control. Cells were incubated for 5 days by replacing the medium and each supernatant at 2-3 days intervals.
- a quantitative polymerase chain reaction was carried out using nucleotides of sequence list 11th and 12th sequence for Bax gene and sequence 13th sequence and 14th sequence for Bcl-2 gene as primers.
- time PCR was performed. Real time PCR was performed by mixing 1 uL of template cDNA, 1 iiL of 10 pmole / uL primer, 12.5 yL of SYBR green PCR master mix (Life technologies, USA), and 9.5 tiL of sterile tertiary distilled water to make a total of 25 mixtures.
- NSC-34 cells were cultured in culture medium containing 10% fetal bovine serum and then suspended using Dulbecco's Modified Eagle Medium containing 1% fetal bovine serum for use in inhibition of apoptosis. 2 niL of medium containing 1% of serum was suspended to include 3 ⁇ 10 5 cells and seeded in 6 well plates.
- each supernatant obtained from 293T cells transfected with pCK-HGF728, pC -HGF723, and pCK-HGFX7 was treated with 30 ⁇ hydrogen peroxide solution selected in the previous experiment, and the concentration of HGF protein was 50 ng / mL. It was treated again.
- As an experimental control a culture medium obtained after transfection of the pCK vector was used. The cell death was observed while culturing the cells for 7 days. Seven days after cell seeding, cells were collected and counted.
- NSC-34 cells were seeded in 6 well plates suspended in 3 ⁇ 10 5 with Dulbecco's Modified Eagle Medium containing 1% fetal bovine serum. The next day, 30 ⁇ hydrogen peroxide solution was treated in each well, and each supernatant obtained from 293T cells transfected with pCK-HGF728, P CK-HGF723, and pCK-HGFX7 was treated so that the concentration of HGF protein was 50 ng / mL. Incubated daily. The supernatant obtained after transfection of the pCK vector was used as an experimental control.
- a quantitative polymerase chain reaction was carried out using nucleotides of sequence list 11th and 12th sequence for Bax gene and sequence 13th sequence and 14th sequence for Bcl-2 gene as primers.
- time PCR was performed. Real time PCR was performed on the template cDNA 1 uL, 10 pmole / uL.
- Primer 1 y L, SYBR green PCR master mix (Li technologies, USA) 12.5 ii L, sterile tertiary distilled water 9.5 were mixed to make a total of 25 mixtures, 50 ° C 2 minutes, 95 ° C 10 minutes.
- pCK-hSODl-wild type and pCK-hS0Dl_G93A were constructed.
- the following experiment was performed.
- NSG-34 cells were suspended in 96 well plates with 1 ⁇ 10 4 Dulbecco's Modified Eagle Medium containing 10% Fetal Bovine Serum and seeded in 96-well plates, the next day pCK, pCK—hSODl ⁇ wild type (WT) , P CK-hS0Dl-G93A mutant (G93A) was transfected using lipofectamine LTX reagent (Li fe technologies, USA) It was. Immediately before transfection, G93A transfected cells were treated with each supernatant obtained from 293T cells transfected with pCK-HGF728 and pCK-HGFX7 so that the concentration of HGF protein was 50 ng / mL. The supernatant obtained after transfection of the pCK vector was used as an experimental control.
- the cell growth was confirmed by treatment with XTT reagent.
- the wild-type hSODl-delivered cells showed similar cell growth with the pCK vector-delivered cells.
- the G93A mutant hSODl-transferred cells showed about 85.8% cell growth compared to the pCK-transmitted cells, which showed lower cell growth than the wild-type hSODl-delivered cells.
- the experimental group treated with PCK-HGFX7 showed about 92.9% of cell growth, showing an effect of inhibiting the decrease of cell growth by delivery of the G93A mutant hSODl (see FIG. 7).
- mice The 10-week-old ALS mice were divided into 4 mice per group, and were divided into Tg-pCK, Tg-pCK—HGF728 (pCK-cHGF from PCT / KR03 / 00548) and Tg-pCK-HGFX7 administration groups, respectively.
- Non-Tg individuals were selected as 6 negative controls (non-Tg).
- the mice of the three experimental groups, except the negative control group were administered intramuscularly.
- the left and right brachial triceps, the forearm muscle, the thigh muscles, the calf muscles were respectively administered, and the dose was administered 50 ⁇ at a concentration of 2 yg / ⁇ .
- the mesh grip test is a method of investigating the grip by placing the mouse over a steel grid with regular grids, flipping it over, and then time the mouse to hang on the steel grid. This is one of the most representative methods for assessing the muscle capacity of mice (Craw l ey JN, 2008).
- mice hanged upside down for an average time of about 9 minutes
- pG-treated mice hanged upside down for 30 seconds on average.
- Individuals who received the pCK-HGF728 plasmid showed a slightly higher mean time than the pCK group, with an average of 49 seconds.
- mice that received pCK-HGFX7 hung upside down longer than mice that received either pCK or pCK-HGF728, and the average time was 3 minutes (see FIG. 8). This shows that pCK-HGFX7 markedly improved the function of the muscles that are ascribed to the grip of ALS mice compared to pCK and pCK-HGF728.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201480058075.3A CN105682676B (zh) | 2013-10-22 | 2014-10-22 | 利用肝细胞生长因子的两种以上的异构体的肌萎缩性侧索硬化症预防或治疗用组合物 |
JP2016546724A JP6240337B2 (ja) | 2013-10-22 | 2014-10-22 | 肝細胞増殖因子の2つ以上のアイソフォームを利用した筋萎縮性側索硬化症の予防又は治療用組成物 |
RU2016119116A RU2639582C2 (ru) | 2013-10-22 | 2014-10-22 | Композиция для предупреждения или лечения бокового амиотрофического склероза с использованием двух или более изоформ фактора роста гепатоцитов |
ES14856385T ES2773305T3 (es) | 2013-10-22 | 2014-10-22 | Composición para la prevención o tratamiento de la esclerosis lateral amiotrófica que utiliza dos o más isoformas del factor de crecimiento de hepatocitos |
CA2926607A CA2926607C (en) | 2013-10-22 | 2014-10-22 | Composition for preventing or treating amyotrophic lateral sclerosis using two or more isoforms of hepatocyte growth factor |
SG11201602452SA SG11201602452SA (en) | 2013-10-22 | 2014-10-22 | Composition for preventing or treating amyotrophic lateral sclerosis using two or more isoforms of hepatocyte growth factor |
MX2016005006A MX2016005006A (es) | 2013-10-22 | 2014-10-22 | Composicion para prevenir a tratar la esclerosis lateral amiotrofica usando dos o mas isoformas del factor de crecimiento de hepatocito. |
BR112016008267A BR112016008267A2 (pt) | 2013-10-22 | 2014-10-22 | Composição para prevenir ou tratar esclerose lateral amiotrófica usando duas ou mais isoformas de fator de crescimento de hepatócito |
US15/030,999 US10639351B2 (en) | 2013-10-22 | 2014-10-22 | Method for treating amyotrophic lateral sclerosis with a polynucleotide encoding two or more isoforms of hepatocyte growth factor |
AU2014337870A AU2014337870B2 (en) | 2013-10-22 | 2014-10-22 | Composition for preventing or treating amyotrophic lateral sclerosis using two or more isoforms of hepatocyte growth factor |
EP14856385.1A EP3061457B1 (en) | 2013-10-22 | 2014-10-22 | Composition for preventing or treating amyotrophic lateral sclerosis using two or more isoforms of hepatocyte growth factor |
HK16107864.0A HK1219873A1 (zh) | 2013-10-22 | 2016-07-06 | 利用肝細胞生長因子的兩種以上的異構體的肌萎縮性側索硬化症預防或治療用組合物 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20130126216 | 2013-10-22 | ||
KR10-2013-0126216 | 2013-10-22 | ||
KR10-2014-0143377 | 2014-10-22 | ||
KR1020140143377A KR101779775B1 (ko) | 2013-10-22 | 2014-10-22 | 간세포 성장인자의 둘 이상의 이형체를 이용한 근위축성 측삭 경화증 예방 또는 치료용 조성물 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2015060650A2 true WO2015060650A2 (ko) | 2015-04-30 |
WO2015060650A3 WO2015060650A3 (ko) | 2015-06-11 |
Family
ID=52993719
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2014/009971 WO2015060650A2 (ko) | 2013-10-22 | 2014-10-22 | 간세포 성장인자의 둘 이상의 이형체를 이용한 근위축성 측삭 경화증 예방 또는 치료용 조성물 |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2015060650A2 (ko) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
WO2000040737A1 (en) | 1998-12-31 | 2000-07-13 | Viromed Limited | High efficiency mammalian gene expression vectors that contain exogenous promoter and entire 5' untranslated region in the upstream from start codon for inherent gene as transcription regulatory site |
-
2014
- 2014-10-22 WO PCT/KR2014/009971 patent/WO2015060650A2/ko active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
WO2000040737A1 (en) | 1998-12-31 | 2000-07-13 | Viromed Limited | High efficiency mammalian gene expression vectors that contain exogenous promoter and entire 5' untranslated region in the upstream from start codon for inherent gene as transcription regulatory site |
Non-Patent Citations (47)
Title |
---|
"Remington's Pharmaceutical Sciences, 19th ed.", 1995, . |
ALTSCHUL ET AL., J. MOL. BIOL., vol. 215, 1990, pages 403 - 10 |
BATT, D. B; G. G. CARMICHAEL, MOL. CELL. BIOL, vol. 15, 1995, pages 4783 - 4790 |
CAPECCHI, M.R., CELL, vol. 22, 1980, pages 479 |
CHAMBER R. ET AL., PROC. NATL. ACAD. SCI USA, vol. 92, 1995, pages 1411 - 1415 |
CHEN; OKAYAMA, MOL. CELL. BIOL, vol. 7, 1987, pages 2745 - 2752 |
COLE, C. N.; T. P. STACY, MOL. CELL. BIOL., vol. 5, 1985, pages 2104 - 2113 |
CORPET ET AL., NUC. ACIDS RES, vol. 16, 1988, pages 10881 - 90 |
COUPAR ET AL., GENE, vol. 68, 1988, pages 1 - 10 |
FLOTTE ET AL., GENE THERAPY, vol. 2, 1995, pages 29 - 37 |
GHOSH-CHOUDHURY ET AL., EMBO J., vol. 6, 1987, pages 1733 - 1739 |
GIL, A. ET AL., CELL, vol. 49, 1987, pages 399 - 406 |
GIMMI, E. R. ET AL., NUCLEIC ACIDS RES., vol. 17, 1989, pages 6983 - 6998 |
GOPAL, MOL. CELL, vol. 5, 1985, pages 1188 - 1190 |
GRAHAM, F.L. ET AL., VIROLOGY, vol. 52, 1973, pages 456 |
HARLAND; WEINTRAUB, J. CELL BIOL., vol. 101, 1985, pages 1094 - 1099 |
HIGGINS; SHARP, CABIOS, vol. 5, 1989, pages 151 - 3 |
HIGGINS; SHARP, GENE, vol. 73, 1988, pages 237 - 44 |
HUANG ET AL., COMP. APPL. BIOSCI, vol. 8, 1992, pages 155 - 65 |
KLASENS, B. I. F. ET AL., NUCLEIC ACIDS RES., vol. 26, 1998, pages 1870 - 1876 |
KUCHERLAPATI R: "Gene transfer", 1986, PLENUM PRESS, article BAICHWAL; SUGDEN: "Vectors for gene transfer derived from animal DNA viruses: Transient and stable expression of transferred genes", pages: 117 - 148 |
LAFACE ET AL., VIOLOGY, vol. 162, 1988, pages 483486 |
MANN ET AL., CELL, vol. 33, 1983, pages 153 - 159 |
MCCARTY ET AL., J. VIROL., vol. 65, 1991, pages 2936 - 2945 |
MCLAUGHLIN ET AL., J. VIROL., vol. 62, 1988, pages 1963 - 1973 |
NEEDLEMAN; WUNSCH, J. MOL. BIO., vol. 48, 1970, pages 443 |
NEUMANN, E. ET AL., EMBO J., vol. 1, 1982, pages 841 |
NICOLAU ET AL., METHODS ENZYMOL., vol. 149, 1987, pages 157 - 176 |
NICOLAU; SENE, BIOCHIM. BIOPHYS. ACTA, vol. 721, 1982, pages 185 - 190 |
PEARSON ET AL., METH. MOL. BIOL, vol. 24, 1994, pages 307 - 31 |
PEARSON; LIPMAN, METHODS IN MOL. BIOL, vol. 24, 1988, pages 307 - 31 |
PUHLMANN M. ET AL., HUMAN GENE THERAPY, vol. 10, 1999, pages 649 - 657 |
RIORDAN, J. R. ET AL., SCIENCE, vol. 245, 1989, pages 1066 - 1073 |
RODRIGUEZ AND DENHARDT: "Vectors: A survey of molecular cloning vectors and their uses", 1988, BUTTERWORTH, article NICOLAS; RUBINSTEIN: "Retroviral vectors", pages: 494 - 513 |
RODRIGUEZ AND DENHARDT: "Vectors: A survey of molecular cloning vectors and their uses.", 1988, BUTTERWORTH, article RIDGEWAY: "Mammalian expression vectors", pages: 467 - 492 |
SAMULSKI ET AL., J. VIROL., vol. 63, 1989, pages 3822 - 3828 |
SCHEK, N ET AL., MOL. CELL BIOL, vol. 12, 1992, pages 5386 - 5393 |
SCIENCE, vol. 266, 1994, pages 1373 - 1376 |
See also references of EP3061457A4 |
SMITH; WATERMAN, ADV. APPL. MATH, vol. 2, 1981, pages 482 |
THIMMAPPAYA, B. ET AL., CELL, vol. 31, 1982, pages 543 - 551 |
TUR-KASPA ET AL., MOL. CELL BIOL., vol. 6, 1986, pages 716 - 718 |
WALSH ET AL., J. CLIN. INVEST., vol. 94, 1994, pages 1440 - 1448 |
WANG G. ET AL., J. CLIN. INVEST., vol. 104, no. 11, 1999, pages R55 - 62 |
WONG, T.K. ET AL., GENE, vol. 10, 1980, pages 87 |
YANG ET AL., PROC. NATL. ACAD. SCI., vol. 87, 1990, pages 9568 - 9572 |
ZHOU ET AL., EXP. HEMATOL. (NY, vol. 21, 1993, pages 928 - 933 |
Also Published As
Publication number | Publication date |
---|---|
WO2015060650A3 (ko) | 2015-06-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2024020346A (ja) | 筋疾患の治療のための改変aavカプシドポリペプチド | |
Gilbert et al. | Prolonged dystrophin expression and functional correction of mdx mouse muscle following gene transfer with a helper-dependent (gutted) adenovirus-encoding murine dystrophin | |
KR101860452B1 (ko) | 간세포 성장인자의 둘 이상의 이형체를 이용한 근위축성 측삭 경화증 예방 또는 치료용 조성물 | |
Ponnazhagan et al. | Suppression of human alpha-globin gene expression mediated by the recombinant adeno-associated virus 2-based antisense vectors. | |
KR20210131370A (ko) | Grn-연관 성인-발병 신경퇴화의 치료를 위한 재조합 아데노-연관 바이러스 | |
BR112020007765A2 (pt) | composições de vírus adeno-associados para restaurar a função do gene hbb e métodos de uso das mesmas | |
WO2008101216A2 (en) | Gamma satellite insulator sequences and their use in preventing gene silencing | |
WO2013065913A1 (ko) | Hgf 이형체를 이용한 당뇨병성 신경병증의 유전자 치료 | |
CA3090226A1 (en) | Adeno-associated virus compositions for restoring pah gene function and methods of use thereof | |
WO2015060650A2 (ko) | 간세포 성장인자의 둘 이상의 이형체를 이용한 근위축성 측삭 경화증 예방 또는 치료용 조성물 | |
JP2019070001A (ja) | 肝細胞増殖因子及びストローマ細胞由来因子1αを用いた末梢動脈疾患の予防または治療用組成物 | |
Takeda et al. | Gene therapy for muscular dystrophies: current status and future prospects | |
JP7244547B2 (ja) | F8遺伝子機能を回復させるためのアデノ随伴ウイルス組成物及びその使用の方法 | |
EP3924376A1 (en) | Optimized lentiviral vector compromising minimal enhancer elements for stem cell gene therapy of hemoglobinopathies | |
WO1999036559A1 (en) | Viral vectors expressing self-polymerizing neuronal intermediate filaments and their use | |
Lim et al. | Gene therapy approaches to ataxias | |
TW202229321A (zh) | 核酸構築體、病毒載體及病毒顆粒 | |
WO2023173125A2 (en) | VECTORS COMBINING ANTI-SICKLING BETA-AS3-GLOBIN WITH ANTI BCEL11A shRNAMIR TO TREAT BETA-HEMOGLOBINOPATHIES | |
KR20240027748A (ko) | Rbm20 돌연변이의 게놈 편집 | |
KR20230038503A (ko) | 샤르코-마리-투스 질환의 치료에 유용한 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14856385 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: 2926607 Country of ref document: CA Ref document number: 2016546724 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2016/005006 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15030999 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112016008267 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2014337870 Country of ref document: AU Date of ref document: 20141022 Kind code of ref document: A |
|
REEP | Request for entry into the european phase |
Ref document number: 2014856385 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014856385 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2016119116 Country of ref document: RU Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 112016008267 Country of ref document: BR Kind code of ref document: A2 Effective date: 20160414 |